Jean Marie Guenot, Taking Big Strides Through Cancer Research Development Projects

Jean Marie Guenot, Taking Big Strides Through Cancer Research Development Projects

 

JeanMarie Guenot, (Ph.D.) is the President/CEO of Amphivena Therapeutics, a company that develops bi-functional antibody therapies. She has worked with both public and private companies such as R&D pharmaceutical, corporate & commercial development companies, venture capital, and project & alliance management co.’s. She has a noteworthy expertise and has immense interest in building or rebuilding companies. Guenot has worked for over 20 years in the biotechnology and pharmaceutical industry.

 

 

Business Ventures

 

 

LinkedIn lists that JeanMarie Guenot is also the founder of SKS Ocular, an ophthalmic company, focused on the ocular drug technologies such as glaucoma therapeutics, macular degeneration, and ocular inflammation. Jean Marie has also served as an advisory to the Hoffmann-La Roche businesses based in China. She also served as Vice President of PDL BioPharma, where she led mergers and acquisitions, licensing, and alliance management for the company; PDL- R&D.

 

 

Career Path

 

Dr. Guenot started her career at Atlas Venture, as noted in her CrunchBase bio, as a venture capital investments manager. She was the principal scientist at R&D – Hoffmann-La Roche, developing metabolic diseases drugs, auto-immune diseases, and oncology. Dr. Guenot specialized in medicinal chemistry, specifically quantum mechanical and methods, protein structure prediction, and drug production &design among others.

 

 

Jean-Marie received her doctorate from the University of California, an MBA from the University of Pennsylvania – the Wharton School. She has projects and group management skills in oncology, cardiovascular diseases, autoimmune diseases, neurology, and ophthalmic diseases.

 

 

Community Work

 

 

Amphivena Therapeutics Inc, under the leadership of Guenot presented optimistic facts on Acute Myeloid Leukemia (AML) Immune-therapy during the 2015 ASCO Yearly Meeting. The positive research results revealed compelling and explicit objective Antibodies; AMV-564 advanced into the development for the AML Treatment.

 

 

The study was accomplished in partnership with top researchers at the Washington University School of Medicine and the Fred Hutchinson Cancer Research Center. Its aim was to observe the antibodies’ strength properties, affinity for the AML cells.

 

 

About Amphivena Therapeutics

 

 

Amphivena Therapeutics is a cancer immune therapy corporation based in San Francisco. Their primary focus is the development of tetravalent, T-cell antibodies for treating hematologic malignancies. The company’s main drug – AMV-564, is a targeted cure for acute myeloid leukemia which the pharmaceutical is presently working on to develop into clinical progress.

Read about Dr. Jeanmarie Guenot and the full Amphivena leadership team here:

http://amphivena.com/leadership/

0 Comments

Add Your Comment: